This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Apr;48(4):612-5.

doi: 10.1007/s00125-005-1705-7. Epub 2005 Mar 10.

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

J J Holst¹, C F Deacon

Affiliations

PMID: 15759106
DOI: 10.1007/s00125-005-1705-7

Comment

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

J J Holst et al. Diabetologia. 2005 Apr.

. 2005 Apr;48(4):612-5.

doi: 10.1007/s00125-005-1705-7. Epub 2005 Mar 10.

Authors

J J Holst¹, C F Deacon

Affiliation

¹ Department of Medical Physiology, University of Copenhagen, The Panum Institute, Blegdamsvej 3, 2200 Copenhagen N, Denmark. holst@mfi.ku.dk

PMID: 15759106
DOI: 10.1007/s00125-005-1705-7

No abstract available

PubMed Disclaimer

Comment in

What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
Ahrén B. Ahrén B. Diabetologia. 2005 Apr;48(4):605-7. doi: 10.1007/s00125-005-1706-6. Epub 2005 Mar 16. Diabetologia. 2005. PMID: 15770467 No abstract available.

Comment on

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
Nauck MA, El-Ouaghlidi A. Nauck MA, et al. Diabetologia. 2005 Apr;48(4):608-11. doi: 10.1007/s00125-005-1704-8. Epub 2005 Mar 11. Diabetologia. 2005. PMID: 15761719 No abstract available.

Similar articles

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
Nauck MA, El-Ouaghlidi A. Nauck MA, et al. Diabetologia. 2005 Apr;48(4):608-11. doi: 10.1007/s00125-005-1704-8. Epub 2005 Mar 11. Diabetologia. 2005. PMID: 15761719 No abstract available.
Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ. Holst JJ. Expert Opin Emerg Drugs. 2004 May;9(1):155-66. doi: 10.1517/eoed.9.1.155.32952. Expert Opin Emerg Drugs. 2004. PMID: 15155141 Review.
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ, Mentlein R. Mest HJ, et al. Diabetologia. 2005 Apr;48(4):616-20. doi: 10.1007/s00125-005-1707-5. Epub 2005 Mar 16. Diabetologia. 2005. PMID: 15770466
What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
Ahrén B. Ahrén B. Diabetologia. 2005 Apr;48(4):605-7. doi: 10.1007/s00125-005-1706-6. Epub 2005 Mar 16. Diabetologia. 2005. PMID: 15770467 No abstract available.
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD, Flatt PR, Bailey CJ. Green BD, et al. Diab Vasc Dis Res. 2006 Dec;3(3):159-65. doi: 10.3132/dvdr.2006.024. Diab Vasc Dis Res. 2006. PMID: 17160910 Review.

See all similar articles

Cited by

Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.
Furuta S, Tamura M, Hirooka H, Mizuno Y, Miyoshi M, Furuta Y. Furuta S, et al. Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):87-96. doi: 10.1007/s13318-013-0119-z. Epub 2013 Feb 23. Eur J Drug Metab Pharmacokinet. 2013. PMID: 23436178
Glucagon-like peptide 1 and appetite.
Dailey MJ, Moran TH. Dailey MJ, et al. Trends Endocrinol Metab. 2013 Feb;24(2):85-91. doi: 10.1016/j.tem.2012.11.008. Epub 2013 Jan 16. Trends Endocrinol Metab. 2013. PMID: 23332584 Free PMC article. Review.
Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
Beraldo JI, Benetti A, Borges-Júnior FA, Arruda-Junior DF, Martins FL, Jensen L, Dariolli R, Shimizu MH, Seguro AC, Luchi WM, Girardi ACC. Beraldo JI, et al. Int J Mol Sci. 2019 Apr 20;20(8):1940. doi: 10.3390/ijms20081940. Int J Mol Sci. 2019. PMID: 31010001 Free PMC article.
Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women.
Otten J, Ryberg M, Mellberg C, Andersson T, Chorell E, Lindahl B, Larsson C, Holst JJ, Olsson T. Otten J, et al. Eur J Endocrinol. 2019 Jun 1;180(6):417-427. doi: 10.1530/EJE-19-0082. Eur J Endocrinol. 2019. PMID: 31042670 Free PMC article. Clinical Trial.
Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System.
Mertens KL, Kalsbeek A, Soeters MR, Eggink HM. Mertens KL, et al. Front Neurosci. 2017 Nov 7;11:617. doi: 10.3389/fnins.2017.00617. eCollection 2017. Front Neurosci. 2017. PMID: 29163019 Free PMC article. Review.

See all "Cited by" articles

References

1. Auton Neurosci. 2004 Jan 30;110(1):36-43 - PubMed
1. Diabetes. 1998 Nov;47(11):1663-70 - PubMed
1. Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 5:S42-7 - PubMed
1. Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E75-81 - PubMed
1. J Clin Endocrinol Metab. 2003 Jun;88(6):2719-25 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal